News

U. of Chicago Booth School Presents Distinguished Alumni Award to Amy Ellis

Prestigious Award Recognizes Outstanding Professional Achievement

Hamilton, NJ (May 2, 2017) — MedAvante, Inc., the leading global clinical data services company dedicated to maximizing signal detection in clinical trials, announced that Amy Ellis, president and co-founder, has been selected to receive the Distinguished Alumni Award (DAA) from the University of Chicago Booth School of Business.

Araclon Biotech Selects MedAvante Virgil Platform for Phase 2 Alzheimer’s Trial

Shared Goal Is Improving Signal Detection and Data Quality through Standardization

Zaragoza, Spain and Hamilton NJ, USA (March 30, 2017) — Araclon Biotech, a Grifols company dedicated to the research and development of therapies and diagnostic methods to be applied to degenerative diseases, and MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, today announced that Araclon Biotech has selected MedAvante’s groundbreaking Virgil® Investigative Study Platform for its upcoming Phase 2 trial in prodromal or very mild Alzheimer’s disease (AD).

MedAvante Names Ropacki Head of Research and Development

Accomplished Clinical Scientist Will Accelerate Company’s Growth

Hamilton, NJ (February 22, 2017) — MedAvante, Inc., the leading global clinical data services company dedicated to maximizing signal detection in clinical trials, announced that Michael T. Ropacki, PhD, has been appointed Vice President, Research and Development to lead the company’s continued expansion of clinical science and signal detection capabilities.

Ian Neilson Joins MedAvante As Global IT Leader

Former Covance Executive Is Accomplished Technology Innovator

Hamilton, NJ (February 8, 2017) — MedAvante, Inc., the leading global clinical data services company dedicated to maximizing signal detection in clinical trials, announced that Ian C. Neilson has accepted the position of Senior Vice President, Global Information Technology to lead the company’s rapidly growing IT operations supporting clinical science and signal detection capabilities.

MedAvante Names Leader for Patient-Focused eSolutions

ePRO Expert Will Enhance Electronic Clinical Outcome Assessment Offerings

Hamilton, NJ (January 26, 2017) — MedAvante, Inc., the leader in technology-based clinical trial services for treatments of central nervous system (CNS) diseases, announced that Susan Vallow, RPh MBA MA, has assumed a new position as Vice President, Patient eSolutions, joining MedAvante from GSK where she was Senior Director and Head of Patient Focused Outcomes.

MedAvante Surpasses 630,000 Electronic Source (eSource) Clinical Trial Assessments

Extends Leadership Position in Electronic Clinical Outcome Assessments (eCOA)

Hamilton, NJ (November 15, 2016) — MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, announced significant advances in the deployment of the groundbreaking Virgil® Investigative Study Platform for global clinical trials as the source (eSource) data platform begins its third year in worldwide use.

MedAvante Unveils Updated Virgil eSource Platform to Further Streamline User Experience, Enhance Data Quality

Hamilton, NJ (October 6, 2016) — MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, announced today the newest release of the Virgil Investigative Study Platform.

MedAvante Presents Research on Preventing PANSS Errors at ISCTM Fall Conference

MedAvante Presents Research on Preventing PANSS Errors at ISCTM Fall Conference.

Continue reading

“Innovation is Everyone’s Job:” MedAvante CEO Paul Gilbert Offers Take on Jumpstarting Innovation at Avoca Quality Consortium

MedAvante, Inc. CEO Paul Gilbert encouraged Pharma industry leaders to challenge conventional thinking during his panel appearance at the Fifth Annual Avoca Quality Consortium Summit in Princeton, NJ.

The panel, “Innovative Collaborations in the Design and Integration of Quality in Clinical Operations,” explored the intersection of innovation, quality, and compliance.

In a dialogue with panel moderator Rob Metcalf, PhD (Vice President of Global Regulatory Affairs, Eli Lilly), Neil McCullough, PhD, MSc (Executive Vice President for Quality Assurance, ICON) and Grace Crawford, (Vice President for Clinical Quality & Compliance, MedImmune), Gilbert urged the industry to rethink an ingrained aversion to risk.

Citing common challenges like committee thinking and changing management trends, Gilbert reminded the audience that failure creates “the prospect of triumph, innovation, and change.” Gilbert stated that the responsibility for improving the industry has to be shared, and cannot be delegated to one individual or department. Innovation, he emphasized, is “everyone’s job.”

Gilbert and his co-founder Amy Ellis have been driving innovations in the Pharma industry for over a decade. First, MedAvante introduced Central Ratings to limit bias and subjectivity in trial assessment. More recently, the company has been the leading innovator in eSource – digital data capture – which has significantly advanced quality in clinical trials.

MedAvante was the first to develop an eSource solution for clinician-reported outcomes in 2009, partnering their 200+ in-house clinicians with software designers to create the Virgil Investigative Study Platform. This innovation enabled MedAvante clinicians’ firsthand knowledge of site workflow and operations to be built into the Virgil Platform.

MedAvante is a proud associate member of the Avoca Quality Consortium. Led by the Avoca Group, the Consortium convenes leaders from over 55 pharma, biotech, and clinical service companies to share knowledge and drive quality and innovation in clinical trials.

Virgil Improves Signal Detection by Minimizing Scoring Discrepancies in AD Clinical Trials

MedAvante research at Alzheimer’s Association International Conference (AAIC) shows Virgil improves signal detection by minimizing scoring discrepancies in AD clinical trials.